A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors.
Ryan J SullivanJeffrey WeberSapna Pradyuman PatelReinhard DummerMatteo S CarlinoDaniel S W TanCeleste LebbéSalvatore SienaElena ElezLance WollenbergMichael D PickardVictor SandorPaolo Antonio AsciertoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with BRAF V600-mutant tumors, which led to the dose selection for the melanoma COLUMBUS study. The safety profile of the combination was consistent with other approved BRAFi plus MEKi regimens, with several differences, including lower rates of dose-limiting pyrexia, arthralgia, and photosensitivity.